0. DOCID:23876 SCORE: 0.00384243322074803
DOCNO: 7951271
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: methods
QUALIFIER: drug therapy
QUALIFIER: statistics & numerical data
AUTHOR: D Faries D
AFFILIATION: Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
PUBTYPE: Journal Article
JOURNALTITLE: Journal of biopharmaceutical statistics.
COUNTRY: UNITED STATES
TITLE: Practical modifications of the continual reassessment method for phase I cancer clinical trials.
PUBDATE: 19940701
The continual reassessment method (1) (CRM) for phase I cancer trials provides improved estimation of the maximum tolerated dose (MTD), and fewer patients receive ineffective dose levels compared to the traditionally used design. However, the CRM has not gained acceptance in practice owing to concerns with administering dose levels that are too toxic. In this article, several conservative modifications of the CRM are introduced. The result is a procedure that improves estimation of the MTD and decreases the use of ineffective doses, without significantly increasing the use of toxic dose levels. The CRM with modification outperforms the traditional method in a simulation study.

1. DOCID:30435 SCORE: 0.00379282411847839
DOCNO: 12206638
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: radiotherapy
AUTHOR: R Subramaniam R
AUTHOR: S J Arnott SJ
AUTHOR: M D Leslie MD
AFFILIATION: St Thomas' Hospital, London, UK.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical oncology (Royal College of Radiologists (Great Britain))
COUNTRY: England
TITLE: Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy.
PUBDATE: 20020801
Repeat radical irradiation of the pelvis is generally not undertaken because of concerns regarding normal tissue damage; in particular to small bowel, bladder and bone. Two patients with carcinoma of the anal canal are presented who had previously been treated by radical pelvic radiotherapy for gynaecological malignancy. Both were re-treated with radical radiotherapy to the pelvis with concomitant chemotherapy. A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities.

2. DOCID:16551 SCORE: 0.00323988422524013
DOCNO: 1958849
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
AUTHOR: J A Wils JA
AFFILIATION: Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Anti-cancer drugs.
COUNTRY: ENGLAND
TITLE: Chemotherapy in pancreatic cancer: a rational pursuit?
PUBDATE: 19910201
A review on the chemotherapy in advanced pancreatic cancer is presented. Pancreatic cancer is an extremely chemotherapy resistant tumor and results of cytostatic drug treatment so far are unsatisfactory. For patients with locally advanced disease the combination of chemo- and radiotherapy may palliate some patients. To date no standard treatment is available and patients should be entered in clinical protocols assessing new treatment options.

3. DOCID:26089 SCORE: 0.00309487437857393
DOCNO: 10687889
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug effects
QUALIFIER: drug therapy
QUALIFIER: metabolism
QUALIFIER: analogs & derivatives
AUTHOR: P S Sastry PS
PUBTYPE: Journal Article
JOURNALTITLE: Medical hypotheses.
COUNTRY: ENGLAND
TITLE: Prevention of progression in chronic myeloid leukemia by altering DNA methylation with a pyridoxine analogue.
PUBDATE: 19991201
Altered DNA methylation is one mechanism by which progression might occur in tumors. Progression in chronic myeloid leukemia (CML) was initially thought to be due to mutations. However, altered DNA methylation might be responsible for the same. An agent whose probable target is DNA methylation has been shown to improve hematopoiesis in CML. Pyridoxine is involved in methylation reactions. At present, the link between dietary factors like pyridoxine and cancer is somewhat tenuous. It is hypothesized that a suitable pyridoxine analogue might, by blocking DNA methylation, prevent progression in CML.

4. DOCID:22340 SCORE: 0.00277148002950633
DOCNO: 9644184
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: pathology
QUALIFIER: metabolism
AUTHOR: Q Ruan Q
AUTHOR: Q Liu Q
AUTHOR: S Tan S
AFFILIATION: Department of Otolaryngology, Tongji Hospital, Tongji Medical University, Wuhan.
PUBTYPE: Journal Article
JOURNALTITLE: Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology.
COUNTRY: CHINA
TITLE: [Effect of human recombinant gamma-interferon on proliferative activity of human laryngeal cancer cell lines]
PUBDATE: 19970201
The effect of human on PCNA expressions of HEP-2 lines was investigated using LSAB (Labelled streptacidin biotin method) with monoclonal antibody Ki-67 (anti-PCNA). The results showed that the PCNA expression which reflects the proliferative activity of cells was dependent on dose of rhu-IFN-gamma in HEP-2 cell lines. Thus, our data suggest that rhu-IFN-gamma might be useful in the treatment of laryngeal cancer because it provides effective cytostatic.

5. DOCID:19551 SCORE: 0.00274175534269548
DOCNO: 7691376
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Stents
QUALIFIER: complications
QUALIFIER: surgery
AUTHOR: P L Mitchell PL
AUTHOR: V J Harvey VJ
AUTHOR: M R Lane MR
AUTHOR: B D Evans BD
AUTHOR: P I Thompson PI
AUTHOR: I Hamilton I
AFFILIATION: Department of Medical Oncology, Auckland Hospital, New Zealand.
PUBTYPE: Journal Article
JOURNALTITLE: The British journal of surgery.
COUNTRY: ENGLAND
TITLE: Palliation of biliary obstruction in patients with advanced breast cancer using endoscopic stents.
PUBDATE: 19930901
Endoscopic insertion of a biliary endoprosthesis was successful in eight patients with extrahepatic biliary obstruction caused by breast cancer metastases. The serum bilirubin level was significantly reduced in seven patients and in four this was accompanied by marked symptomatic improvement. Endoprostheses required replacement after a median of 8 (range 3-127) weeks. Two patients responding to systemic anticancer therapy survived 27 and 43 months. Endoscopically placed stents offer effective palliation of extrahepatic biliary obstruction caused by metastatic breast cancer and long-term survival may be possible.

6. DOCID:17405 SCORE: 0.00273514061651874
DOCNO: 1493433
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: R Weide R
AUTHOR: C Görg C
AUTHOR: K H Pflüger KH
AUTHOR: A Ramaswamy A
AUTHOR: A Steinmetz A
AUTHOR: S Falk S
AUTHOR: W B Schwerk WB
AFFILIATION: Department of Internal Medicine, Philipps University, Marburg, Germany.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Leukemia & lymphoma.
COUNTRY: SWITZERLAND
TITLE: Concomitant primary low grade non-Hodgkin's lymphoma of the spleen and breast carcinoma.
PUBDATE: 19920701
A case is described of a 71 year old woman with scirrhous breast cancer and multiple hypoechogenic lesions in the spleen. The patient was treated successfully by mastectomy and splenectomy. Morphologic examination of the spleen showed a primary, centroblastic-centrocytic, low grade non-Hodgkin's lymphoma. Eight months after splenectomy the patient still remains in complete remission.

7. DOCID:23055 SCORE: 0.00271759168369485
DOCNO: 8978796
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: administration & dosage
AUTHOR: Y Nomura Y
AFFILIATION: Dept. of Breast Surgery, National Kyushu Cancer Center.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gan to kagaku ryoho. Cancer & chemotherapy.
COUNTRY: JAPAN
TITLE: [Adriamycin--breast cancer]
PUBDATE: 19961201
The significance of doxorubicin (ADR) was reviewed in the treatment of advanced as well as early breast cancer. The history of ADR treatment, mainly as a combination of CAF, or FAC, has revealed that ADR is still the key drug for breast cancer, the response rate being 40-60%. A multivariate analysis in 182 advanced breast cancer cases showed that the predictive factor was the dominant site of metastasis, and performance status (PS). Overall survival was determined with the age, the dominant site of metastasis, and PS. Recently the combination chemotherapy including ADR was evaluated to be equivalent to CMF type chemotherapy in the adjuvant settings.

8. DOCID:21093 SCORE: 0.00246467476989902
DOCNO: 7705135
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Tomography, Emission-Computed
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: radionuclide imaging
AUTHOR: R W Ward RW
AUTHOR: R Chin R
AUTHOR: J W Keyes JW
AUTHOR: E F Haponik EF
AFFILIATION: Section on Pulmonary and Critical Care Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston Salem, NC, USA.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Chest.
COUNTRY: UNITED STATES
TITLE: Digital clubbing. Demonstration with positron emission tomography.
PUBDATE: 19950401
Digital clubbing is a classic cutaneous manifestation of pulmonary disease, but its mechanism is unknown. We describe a patient with lung cancer and clubbing in whom positron emission tomography (PET) demonstrated, for the first time, that increased glucose metabolism occurs at the nailbed. PET may contribute to future investigations of digital clubbing.

9. DOCID:27603 SCORE: 0.00241401435121642
DOCNO: 9932085
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Taxoids
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: C Couteau C
AUTHOR: J P Armand JP
AFFILIATION: Service d'oncologie médicale, hôpital Tenon, Paris, France.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Bulletin du cancer.
COUNTRY: FRANCE
TITLE: [Irinotecan-containing combinations in solid tumors, except colonic carcinomas]
PUBDATE: 19981201
Irinotecan is a new topoisomerase I inhibitor. It has demonstrated antitumor activity in solid tumors, independently of the histologic type, and in squamous cervical carcinoma. Its original mechanism of action offers the possibility to combine it with other drugs. In vitro and in vivo studies have demonstrated synergistic activity between irinotecan, cisplatin and etoposide. This article reviews the main published phases I and II studies with irinotecan. The limiting toxicity of combination schedules in neutropenia. The best results were obtained with the association cisplatin-irinotecan in lung cancer. For the combination etoposide-irinotecan the best schedule of administration remains to be determined.

10. DOCID:22904 SCORE: 0.00225407086764999
DOCNO: 8938272
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: immunology
QUALIFIER: pharmacology
AUTHOR: K R Irvine KR
AUTHOR: N P Restifo NP
AFFILIATION: Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in cancer biology.
COUNTRY: UNITED STATES
TITLE: The next wave of recombinant and synthetic anticancer vaccines.
PUBDATE: 19951201
The identification of tumor-associated antigens (TAA) recognized by T lymphocytes makes the development of antigen-specific synthetic and recombinant vaccines possible. The expression of TAA within a recombinant vector increases control over the kinetics and quantity, the molecular form, and the subcellular location of the immunogen delivered. The next generation of antitumor vaccines employs cytokines and costimulatory molecules expressed in concert with TAA that are capable of augmenting the activation and proliferation of antitumor immune responses. The ultimate goal of these new strategies, the treatment of established cancer, is now being realized in animal models.

11. DOCID:19973 SCORE: 0.00223535261794064
DOCNO: 1831702
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: analysis
QUALIFIER: methods
AUTHOR: Z Chen Z
AFFILIATION: Institute of Oncology, Beijing.
PUBTYPE: Journal Article
JOURNALTITLE: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.
COUNTRY: CHINA
TITLE: [The development of DELFIA with novel tumor monoclonal antibodies E-11 and G-4]
PUBDATE: 19910201
Monoclonal antibodies E-11 and G-4 were purified by Sepharose 4B column chromatography and labelled with europium as tracer. The solid-phase antibodies were prepared by attaching pure E-11 and G-4 to polysterene strips. The supernatant of 8611 cell culture or perchloric acid extracts from ovarian cancer tissues provided standard antigens. The solid-phase sandwich-type DELFIAs for monoclonal antibodies E-11 and G-4 were thus established, and the resulting standard curves were extremely steep. The ratio of CPS in high-concentration tubes to CPS in the zero tube exceeded 300:1, indicating the very high sensitivity and accuracy of this method.

12. DOCID:27528 SCORE: 0.00221711336395569
DOCNO: 11859661
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Prostatectomy
QUALIFIER: surgery
AUTHOR: D Vordos D
AUTHOR: V Delmas V
AUTHOR: J F Hermieu JF
AUTHOR: V Ravery V
AUTHOR: J P Lassau JP
AUTHOR: L Boccon-Gibod L
AFFILIATION: Institut d'Anatomie, UFR biomédicale, Université Paris V, Clinique Urologique, Hôpital Bichat, Paris, France.
PUBTYPE: Journal Article
JOURNALTITLE: Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie.
COUNTRY: France
TITLE: [Can a precise vesiculectomy be performed during radical prostatectomy?]
PUBDATE: 20011201
OBJECTIVE: To define the anatomical landmarks allowing precise vesiculectomy to be performed during radical prostatectomy for cancer. MATERIAL AND METHODS: 12 non-formalin-preserved anatomical subjects were dissected as during retropubic and perineal prostatectomy, with and without coloured latex vascular injection. RESULTS: Three anatomical landmarks were defined: 1) Denonvilliers' fascia; 2) vas deferens; 3) arteries supplying the seminal vesicles. CONCLUSIONS: These three anatomical landmarks ensure: complete resection, preservation of adjacent anatomical structures and elective haemostasis.

13. DOCID:27631 SCORE: 0.00221711116433117
DOCNO: 9773039
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: pathology
QUALIFIER: secondary
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: secondary
AUTHOR: J P Ferroir JP
AUTHOR: J Cadranel J
AUTHOR: A Khalil A
AUTHOR: C Lebreton C
AUTHOR: S Contant S
AUTHOR: B Milleron B
AFFILIATION: Service de Neurologie, Hôpital Tenon, Paris.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Revue neurologique.
COUNTRY: FRANCE
TITLE: [Intramedullary metastases of bronchogenic carcinoma. Two cases]
PUBDATE: 19980201
Intramedullary metastases are uncommon. We report two cases in patients with small cell bronchogenic cancer. The clinical diagnosis was supported by T1 magnetic resonance imaging after gadolinium injection. A unique medullary metastasis associated with other metastatic localizations was observed in the first patient and multiple intramedullary metastases alone in the second. These secondary intramedullary localizations were highly sensitive to chemotherapy after the first monthly cure in the first patient and after the third in the second patient. We emphasize the importance of chemotherapy in such cases, usually associated with focal radiotherapy.

14. DOCID:25960 SCORE: 0.00219261164885881
DOCNO: 11325208
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: prevention & control
QUALIFIER: etiology
QUALIFIER: drug therapy
AUTHOR: G Mathé G
PUBTYPE: Editorial
JOURNALTITLE: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie.
COUNTRY: France
TITLE: Impotence-free hormonal treatment of prostate cancer.
PUBDATE: 20010401
Since the protein-specific antigen (PSA) test is systematically used in some countries for cancer detection, many asymptomatic and latent cancer patients are uselessly victims of anxiety, hormonotherapy, and impotence, when they are not demolished by surgery and/or radiotherapy's local and/or regional complications. We propose to conduct a study of dexamethasone as treatment of such latent, small and even wrongly diagnosed cases. Certainly it exerts at small doses a discrete hormonal effect. But it has an anti-growth factor effect, which may explain its often beneficial action on prostate cancer with resistance to androgen inhibitors.